Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signs and Symptoms, Respiratory
|
10 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Metastatic non-small cell lung cancer
|
11 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.100 | 1.000 | 12 | 2013 | 2019 | ||||||
Carcinoma breast stage IV
|
14 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||
CNS metastases
|
14 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
Exanthema
|
14 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
HER2 gene amplification
|
14 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
Secondary malignant neoplasm of bone
|
18 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 1.000 | 2 | 2015 | 2017 | ||||||
Nodule
|
19 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 0.500 | 2 | 2015 | 2018 | ||||||
Secondary malignant neoplasm of lung
|
20 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 1.000 | 2 | 2014 | 2016 | ||||||
Seborrheic keratosis
|
21 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Hyperplastic Polyp
|
22 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2020 | 2020 | ||||||
Metastatic malignant neoplasm to brain
|
28 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.050 | 1.000 | 5 | 2010 | 2018 | ||||||
Laryngeal Squamous Cell Carcinoma
|
30 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Secondary malignant neoplasm of liver
|
34 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Lung Neoplasms
|
39 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.060 | 1.000 | 6 | 2012 | 2019 | ||||||
Progressive cGVHD
|
40 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.040 | 1.000 | 4 | 2011 | 2019 | ||||||
Progressive Neoplastic Disease
|
40 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.040 | 1.000 | 4 | 2011 | 2019 | ||||||
Diarrhea
|
63 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Tumor Progression
|
72 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Secondary Neoplasm
|
85 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Triple-Negative Breast Carcinoma
|
96 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||
Triple Negative Breast Neoplasms
|
99 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||
Carcinoma
|
103 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.020 | 1.000 | 2 | 2014 | 2015 | ||||||
Small cell carcinoma of lung
|
125 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.030 | 1.000 | 3 | 2007 | 2013 | ||||||
Adenocarcinoma
|
168 | 0.568 | 0.560 | 7 | 55191822 | missense variant | T/A;G | snv | 0.100 | 0.941 | 34 | 2005 | 2020 |